title: [Clinical and vascular effects of ACE inhibitor enalapril in combination with thiaside-like diuretic indapamide in hypertensive outpatients. Results of the multicenter trial POEMA].
abstract: OBJECTIVE
  To evaluate efficacy and safety of a 6-month treatment of 237 patients with arterial hypertension (AH) of degree 1-3 with ACE inhibitor enalapril (mean dose 21.9 +/- 9.0 mg/day), 49.4% of which received adjuvant indapamide (2.5 mg/day), to study effects of this therapy on rigidity of the major arteries by dynamics of pulse wave velocity (PWV) and US rigidity index beta (RIB).
  
  
  METHODS
  The study included only patients with initially elevated PWV which was detected in 266 (53%) of 501 examinees.
  
  
  RESULTS
  Lowering of systolic and diastolic blood pressure (BP) was 16.8 and 14.0% to treatment month 3 and, in addition, 1.6 and 1. 7% to month 6, respectively (p < 0.001). Target BP (< or = 140/90 mm Hg) was achieved in 82.7% patients. During the trial 3 (1.2%) patients withdrew because of severe cough. Slowdown of PWV measured by brachiomalleolar (PWVbm) and carotid-femoral (PWVcf) methods was equal in the course of the trial and made up 2.45 and 6.1% to treatment month 3 (p < or = 0.05 for both) and additional 3.25 and 7.4% to month 6 (p < 0.001 for both), respectively. High PWV normalized completely in 42.6% patients. After 6 months of the trial US RIB decreased by 30.5% (p < or = 0.001). The correlation analysis detected a significant correlation between SAP fall and PWV decrease only during the first 3 months of therapy (r = 0.402, p = 0.005). In month 3-6 the correlation became insignificant (r = 0.28, p = 0.055).
  
  
  CONCLUSIONS
  Combination of enalapril and indapamide is effective and safe in outpatients with arterial hypertension of the first-third degree and baseline high rigidity of the vascular wall. This treatment reduces PWV and rigidity of the major arteries associated with BP lowering (in the treatment month 1-3) and a vasoprotective effect of the drugs.
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Belenkov
authors.forename: F T
authors.initials: FT
authors.lastname: Ageev
authors.forename: Ia A
authors.initials: IaA
authors.lastname: Orolova
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Abrosimova
authors.forename: E G
authors.initials: EG
authors.lastname: Volkova
authors.forename: L I
authors.initials: LI
authors.lastname: Gapon
authors.forename: L I
authors.initials: LI
authors.lastname: Katel'nitskaia
authors.forename: A O
authors.initials: AO
authors.lastname: Kondari
authors.forename: I F
authors.initials: IF
authors.lastname: Patrusheva
authors.forename: I V
authors.initials: IV
authors.lastname: Fomin
authors.forename: R A
authors.initials: RA
authors.lastname: Khokhlov
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007190:Indapamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D011673:Pulsatile Flow / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects* / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D004656:Enalapril; D007190:Indapamide